• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed

    2/25/21 3:05:43 PM ET
    $CGIX
    Medical Specialities
    Health Care
    Get the next $CGIX alert in real time by email
    SC 13D 1 sc_13d.htm SCHEDULE 13D Schedule 13D

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    CANCER GENETICS INC

    (Name of Issuer)

    Common Shares

    (Title of Class of Securities)

    13739U203

    (CUSIP Number)

    FiveT Investment Management Ltd
    c/o DMS Corporate Services, Suite 5B201, 2nd Floor, One Nexus Way
    Camana Bay, Grand Cayman, Cayman Islands KY1-1108
    +1 345 749 2552

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)

    February 11, 2021

    (Date of Event which Requires Filing of this Statement)

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
     

    CUSIP No. 13739U203

     

    13D

     

    Page 2 of 6 Pages

     

     

     

     

    1.

     

    NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    FiveT Investment Management Ltd

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    
    ¨
    (b)    
    ¨

     

     

    3.

     

    SEC USE ONLY
     

     

     

    4.

     

    SOURCE OF FUNDS (see instructions)
     
    WC

     

     

    5.

     

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     ¨

     

     

    6.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Cayman Islands

     

     

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

     

    7.

     

    SOLE VOTING POWER
     
    00,000

     

    8.

     

    SHARED VOTING POWER
     
    00,000

     

    9.

     

    SOLE DISPOSITIVE POWER
     
    00,000

     

    10.

     

    SHARED DISPOSITIVE POWER
     
    00,000

     

    11.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    00,000

     

     

    12.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
    (see instructions)    
    ¨

     

     

    13.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    0.00%

     

     

    14.

     

    TYPE OF REPORTING PERSON (see instructions)

    CO

     

     

     

      
     

    CUSIP No. 13739U203

     

    13D

     

    Page 3 of 6 Pages

     

     

     

     

    1.

     

    NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    FiveT Capital AG

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    
    ¨
    (b)    
    ¨

     

     

    3.

     

    SEC USE ONLY
     

     

     

    4.

     

    SOURCE OF FUNDS (see instructions)
     
    OO

     

     

    5.

     

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     ¨

     

     

    6.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Switzerland

     

     

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

     

    7.

     

    SOLE VOTING POWER
     
    00,000

     

    8.

     

    SHARED VOTING POWER
     
    00,000

     

    9.

     

    SOLE DISPOSITIVE POWER
     
    00,000

     

    10.

     

    SHARED DISPOSITIVE POWER
     
    00,000

     

    11.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    00,000

     

     

    12.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
    (see instructions)    
    ¨

     

     

    13.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    0.00%

     

     

    14.

     

    TYPE OF REPORTING PERSON (see instructions)

    IA

     

     

     

     
     

    CUSIP No. 13739U203

     

    13D

     

    Page 4 of 6 Pages

     

     

     

     

    Item 1.  Security and Issuer.

    Cusip:

    13739U203

    Issuer:

    Cancer Genetics Inc
    201 Route 17 North
    2nd Floor
    Rutherford, NJ 07070

     

    Item 2.  Identity and Background.

    Name of person filing:

    FiveT Investment Management Ltd
    FiveT Capital AG

    Registered address or principle place of business:

    FiveT Investment Management Ltd
    c/o DMS Corporate Services, Suite 5B201, 2nd Floor, One Nexus Way,
    Camana Bay, Grand Cayman, Cayman Islands KY1-1108

    FiveT Capital AG
    Allmendstrasse 140, 8041 Zurich, ZH, Switzerland

     

    Item 5.  Interest in Securities of the Issuer.

    As of the date of this Schedule 13D, the Reporting Persons acquired an aggregate of 666,667 shares of Common Stock, consisting of 666,667 shares held by the FiveT Investment Management Ltd (the “Shares”).  The Shares represent 6.31% of the Common Stock outstanding.  Subsequently, the Reporting Persons sold an aggregate of 666,667 Shares.  As of the date of this Schedule 13D, the Reporting Persons beneficially own an aggregate of 0 shares of Common Stock. The Shares represent 0.00% of the Common Stock outstanding.

     

    Item 7.  Material to Be Filed as Exhibits.

    Schedule I

     

     
     

    CUSIP No. 13739U203

     

    13D

     

    Page 5 of 6 Pages

     

     

     

     

     

     

    Schedule I

     

    This Schedule sets forth information with respect to each purchase and sale of Shares which was effectuated by a Reporting Person in the last 60 days since the date of the event which requires filing of this Statement. 

    Unless otherwise indicated, all transactions were effectuated in the open market through a broker.

     

    Trade Date

    Shares Purchased (Sold)

    Price Per Share ($)

    02/11/2021

    666,667

    6.30

    02/11/2021

    (100,000)

    6.83

    02/11/2021

    (428,500)

    7.07

    02/12/2021

    (36,901)

    6.79

    02/16/2021

    (101,266)

    7.01

     

     

     

     

     
     

    CUSIP No. 13739U203

     

    13D

     

    Page 6 of 6 Pages

     

     

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    FIVET INVESTMENT MANAGEMENT LTD

    /s/ Wieland Kreuder

    Authorized Person

    February 16, 2021

     

    Get the next $CGIX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CGIX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CGIX
    SEC Filings

    View All

    SEC Form 3 filed by Cancer Genetics, Inc.

    3 - Vyant Bio, Inc. (0001349929) (Issuer)

    4/1/21 7:03:48 PM ET
    $CGIX
    Medical Specialities
    Health Care

    SEC Form 10-K filed by Cancer Genetics, Inc.

    10-K - CANCER GENETICS, INC (0001349929) (Filer)

    3/31/21 6:01:06 AM ET
    $CGIX
    Medical Specialities
    Health Care

    SEC Form 8-K filed by Cancer Genetics, Inc.

    8-K - CANCER GENETICS, INC (0001349929) (Filer)

    3/25/21 9:17:14 AM ET
    $CGIX
    Medical Specialities
    Health Care

    $CGIX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cancer Genetics and StemoniX Announce Merger Closing

    Cancer Genetics, Inc. Renamed to Vyant Bio, Inc. Vyant Bio, Inc. will begin trading on Nasdaq under the symbol VYNT CHERRY HILL, N.J., March 31, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company” or “CGI”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, and StemoniX, Inc. (“StemoniX”), a company empowering the discovery of new medicines through the convergence of novel human biology and software technologies, today announced their recently approved transaction has closed, and in connection with the merger, Cancer Genetics, Inc. was renamed Vyant Bio, Inc. (“Vyant Bio”) effective March 30, 2021. StemoniX will operate as a wholly-owned subsidiary of t

    3/31/21 6:30:00 AM ET
    $CGIX
    Medical Specialities
    Health Care

    Cancer Genetics Announces Shareholder Approval of All Proposals in Connection with the Proposed Merger with StemoniX

    Combined entity creates an innovative platform to de-risk and accelerate the discovery and development of preclinical and clinical pipelines with biopharma partners as well as the proprietary pipeline of the combined company RUTHERFORD, N.J., March 25, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced the results of its March 24, 2021 shareholder meeting to approve the upcoming merger with StemoniX, Inc. ("StemoniX"). At a Special Meeting of Stockholders, CGI’s stockholders, upon the unanimous recommendation of the board of directors of CGI: (a) voted in favor of the issuance of shares of Commo

    3/25/21 9:15:00 AM ET
    $CGIX
    Medical Specialities
    Health Care

    Cancer Genetics Announces Roland J. Carrillo, PhD as Vice President of Business Development

    RUTHERFORD, N.J., March 18, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today the appointment of Roland J. Carrillo, PhD as the Vice President of Business Development. Dr. Carrillo brings over a decade of experience with drug discovery and translational science with extensive knowledge of business development, marketing, and sales operations. His latest role was at Crown Bioscience, where he held positions as Senior Director for Sales Operations and Director of Business Development. He also led efforts in sales enablement, research service commercialization, and new business unit creation.

    3/18/21 8:30:00 AM ET
    $CGIX
    Medical Specialities
    Health Care

    $CGIX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: John R Fletcher was granted 8,676 units of Common Stock

    4 - Vyant Bio, Inc. (0001349929) (Issuer)

    4/1/21 9:48:08 PM ET
    $CGIX
    Medical Specialities
    Health Care

    SEC Form 4 filed by Marcus Boehm

    4 - Vyant Bio, Inc. (0001349929) (Issuer)

    4/1/21 9:46:47 PM ET
    $CGIX
    Medical Specialities
    Health Care

    SEC Form 4 filed by Joanna Horobin

    4 - Vyant Bio, Inc. (0001349929) (Issuer)

    4/1/21 9:32:36 PM ET
    $CGIX
    Medical Specialities
    Health Care

    $CGIX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed

    SC 13D - CANCER GENETICS, INC (0001349929) (Subject)

    2/25/21 3:05:43 PM ET
    $CGIX
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - CANCER GENETICS, INC (0001349929) (Subject)

    2/10/21 9:43:25 PM ET
    $CGIX
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - CANCER GENETICS, INC (0001349929) (Subject)

    2/10/21 9:26:44 PM ET
    $CGIX
    Medical Specialities
    Health Care

    $CGIX
    Leadership Updates

    Live Leadership Updates

    View All

    Cancer Genetics Announces Roland J. Carrillo, PhD as Vice President of Business Development

    RUTHERFORD, N.J., March 18, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today the appointment of Roland J. Carrillo, PhD as the Vice President of Business Development. Dr. Carrillo brings over a decade of experience with drug discovery and translational science with extensive knowledge of business development, marketing, and sales operations. His latest role was at Crown Bioscience, where he held positions as Senior Director for Sales Operations and Director of Business Development. He also led efforts in sales enablement, research service commercialization, and new business unit creation.

    3/18/21 8:30:00 AM ET
    $CGIX
    Medical Specialities
    Health Care